COMP <GO>
IBRX vs LLY // PIOTROSKI F-SCORE QUALITY
ImmunityBio Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: IBRX 3
— LLY 11
▲ PIOTROSKI F-SCORE QUALITY LEADER: LLY
LAST: $8.29 (-5.15%) • MKT CAP: $9.26B
piotroski-score
6/9
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
piotroski-score
9/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IBRX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IBRX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 83.64% | +12.36 | IBRX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.30% | 32.36% | -59.66 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.33% | 2.30% | -5.63 | LLY | /fcf-yield <GO> |
| Operating Margin | -60.00% | 40.21% | -100.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 31.90% | -91.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 45.51% | +134.49 | IBRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 9.29 | -8.84 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.77% | +0.33 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.8 | 77.9 | -34.07 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 0.51 | +0.54 | IBRX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.0x | 26.3x | +2.75 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.26B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IBRX REV | LLY REV | IBRX GROSS % | LLY GROSS % | IBRX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $113.3M | $65.18B | 99.3% | 83.0% | -$308.8M | $16.81B |
| FY 2024 | $14.7M | $45.04B | 100.0% | 81.3% | -$398.1M | $8.82B |
| FY 2023 | $622.0K | $34.12B | 44.0% | 79.3% | -$366.8M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IBRX // BETA 1.05
LLY // BETA 0.51